BMRNBioMarin Pharmaceutical Inc.
$54.80+0.81% 1Y
$54.80
$49.6752 weeks$70.23
The financials
BioMarin Pharmaceutical Inc. by the numbers
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of $990M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 80% and net income of $45M (4.5% of revenue). For the full year FY2025, revenue was $3.22B (+13% year on year) and net income $349M. Its largest product in Q2 2026 was VOXZOGO at $253M, 26% of the disclosed total, just ahead of VIMIZIM at 20%. The next results filing is expected around Jan 11, 2027, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $990M | $825M | +20% |
| Gross profit | $787M | $675M | +17% |
| Operating income | $111M | $277M | −60% |
| Net income | $45M | $241M | −81% |
| Diluted EPS | $0.23 | $1.23 | −81% |
| Product | Revenue | Share |
|---|---|---|
| VOXZOGO | $253M | 26% |
| VIMIZIM | $194M | 20% |
| NAGLAZYME | $135M | 14% |
| PALYNZIQ | $135M | 14% |
| GALAFOLD | $106M | 11% |
| BRINEURA | $51M | 5.2% |
| ALDURAZYME | $44M | 4.4% |
| POMBILITIOPFOLDA | $30M | 3.1% |
| KUVAN | $24M | 2.5% |
| ROCTAVIAN | $12M | 1.2% |
| Royalty And Other | $5.3M | 0.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $989.7M (+29%)
PALYNZIQ grew +28% year on yearRoyalty And Other -57% year on year
Segment Latestquarter on quarteryear on year
- VOXZOGO$252.5M$252.5Mquarter on quarter +15%year on year +14%+15%+14%
- VIMIZIM$194.4M$194.4Mquarter on quarter -7.5%year on year -9.8%-7.5%-9.8%
- NAGLAZYME$135.3M$135.3Mquarter on quarter +4.0%year on year +5.0%+4.0%+5.0%
- PALYNZIQ$135.2M$135.2Mquarter on quarter +51%year on year +28%+51%+28%
- GALAFOLD$105.7M$105.7Mquarter on quarter n/ayear on year n/an/an/a
- BRINEURA$51.4M$51.4Mquarter on quarter +9.1%year on year +5.5%+9.1%+5.5%
- ALDURAZYME$43.5M$43.5Mquarter on quarter +18%year on year -23%+18%-23%
- POMBILITIOPFOLDA$30.3M$30.3Mquarter on quarter n/ayear on year n/an/an/a
- KUVAN$24.4M$24.4Mquarter on quarter +2.4%year on year -9.6%+2.4%-9.6%
- ROCTAVIAN$11.7M$11.7Mquarter on quarter +344%year on year +27%+344%+27%
- Royalty And Other$5.3M$5.3Mquarter on quarter -13%year on year -57%-13%-57%